

DAFTAR PUSTAKA

1. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. *Glob Initiat Chronic Obstr Lung Diseases.* 2020;4.
2. World health organization. Burden of COPD [Internet]. Available from: <https://www.who.int/respiratory/copd/burden/en/>
3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *The Lancet* [Internet]. 2007 Sep [cited 2021 Oct 12];370(9589):765–73. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673607613804>
4. Adeloye D, Lee C, Papana A, Nair H, Sridhar D, Chan KY. Global and regional estimates of COPD prevalence : Systematic review and meta – analysis. *J Glob Health.* 2015;5(2):1–16.
5. Regional COPD working group. COPD prevalence in 12 Asia-pasiefic countries and region: projection based on the COPD prevalence estimation model. *Respirology.* 2013;8:192–8.
6. Kementrian kesehatan RI. Laporan nasional riskesdas 2013. Lembaga penerbit badan penelitian dan pengembangan kesehatan.; 2013.
7. Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. *Int J Chron Obstruct Pulmon Dis* [Internet]. 2018 Oct [cited 2021 Oct 17];Volume 13:3341–8. Available from: <https://www.dovepress.com/role-of-inflammatory-cells-in-airway-remodeling-in-copd-peer-reviewed-article-COPD>
8. Pavord ID, Yousaf N, Birring SS. Chronic obstructive non-smokers. *Lancet.* 2009;374(9706):1964.
9. Barnes PJ. Alveolar macrophage as orchestrators of COPD. *Basic Sci Rev.* 2009;1(1):59–70.
10. Anzueto A. Impact of exacerbations on COPD. *Eur Respir.* 2010;113–8.
11. Profita M, Sala A, Bonanno A, Riccobono L, Ferraro M, Grutta S, et al. Chronic obstructive pulmonary disease and neutrophil infiltration : role of cigarette smoke and cyclooxygenase products. *Am J Physiol Lung Cell Mol Physiol.* 2010;298(23):261–9.

12. Zou Y, Chen X, Liu J, Zhou D bo, Kuang X, Xiao J, et al. Serum IL-1 β ; and IL-17 levels in patients with COPD: associations with clinical parameters. *Int J Chron Obstruct Pulmon Dis* [Internet]. 2017 Apr [cited 2021 Oct 12];Volume 12:1247–54. Available from: <https://www.dovepress.com/serum-il-1beta-and-il-17-levels-in-patients-with-copd-associations-wit-peer-reviewed-article-COPD>
13. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1 β Causes Pulmonary Inflammation, Emphysema, and Airway Remodeling in the Adult Murine Lung. *Am J Respir Cell Mol Biol* [Internet]. 2005 Apr [cited 2021 Oct 12];32(4):311–8. Available from: <http://www.atsjournals.org/doi/abs/10.1165/rcmb.2004-0309OC>
14. Perhimpunan Dokter Paru Indonesia. PPOK (Penyakit Paru Obstruktif Kronik). Diagnosis dan Penatalaksanaan. Jakarta: Perhimpunan dokter paru Indonesia; 2016. 1–78 p.
15. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J* [Internet]. 2008 May 14 [cited 2021 Oct 14];32(4):962–9. Available from: <http://erj.ersjournals.com/cgi/doi/10.1183/09031936.00012408>
16. de Torres JP, Casanova C, Pinto-Plata V, Varo N, Restituto P, Cordoba-Lanus E, et al. Gender Differences in Plasma Biomarker Levels in a Cohort of COPD Patients: A Pilot Study. Gaggar A, editor. *PLoS ONE* [Internet]. 2011 Jan 18 [cited 2021 Oct 12];6(1):e16021. Available from: <https://dx.plos.org/10.1371/journal.pone.0016021>
17. Brode SK. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. :7.
18. MacNee W. Pathology, pathogenesis, and pathophysiology. *BMJ* [Internet]. 2006 May 20 [cited 2021 Oct 12];332(7551):1202–4. Available from: <https://www.bmjjournals.org/lookup/doi/10.1136/bmj.332.7551.1202>
19. Sng J, Thomas P. COPD: Immunopathogenesis and Immunological Markers. *Adv Res* [Internet]. 2015 Jan 10 [cited 2021 Oct 12];3(2):221–35. Available from: <http://www.sciedomain.org/abstract.php?iid=695&id=31&aid=6470>
20. Yudhawati R, Prasetyo YD. Imunopatogenesis Penyakit Paru Obstruktif Kronik. *J Respirasi* [Internet]. 2019 Apr 25 [cited 2021 Oct 12];4(1):19. Available from: <https://ejournal.unair.ac.id/JR/article/view/12936>

21. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Airways Group, editor. Cochrane Database Syst Rev [Internet]. 2015 Feb 24 [cited 2021 Oct 12]; Available from: <https://doi.wiley.com/10.1002/14651858.CD003793.pub3>
22. Senior SM, Shapiro SD. Chronic obstructive pulmonary disease: epidemiology, pathophysiology and pathogenesis. In : Fishman AP, Elias JA, Grippi MA, Kaiser LR, Senior RM, editors. Pulmonary diseases and disorders. 3rd ed. New York: McGraw-Hill Companies; 1998. 659–678 p.
23. Hurst JR, Locantore N, Miller B, MacNee W, Rennard S, Wedzicha JA. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 2010;11.
24. Silva BSA, Lira FS, Ramos D, Uzeloto JS, Rossi FE, Freire APCF, et al. Severity of COPD and its relationship with IL-10. *Cytokine* [Internet]. 2018 Jun [cited 2021 Oct 18];106:95–100. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1043466617303320>
25. Idris R, Ilyas M, Arief E, Bakri S, Aman AM, Ra H. Profile of Vitamin D and Interleukin-8 in COPD Exacerbation. *Clin Med*. 2020;07(03):11.
26. Bazzoni F, Beutler B. The Tumor Necrosis Factor Ligand and Receptor Families. Flier JS, Underhill LH, editors. *N Engl J Med* [Internet]. 1996 Jun 27 [cited 2021 Oct 18];334(26):1717–25. Available from: <http://www.nejm.org/doi/10.1056/NEJM199606273342607>
27. Fujita M, Hiroshi O, Ikemage S, Harada E, Matsumoto T, Uchino J, et al. Critical role of tumor necrosis factor receptor 1 in the pathogenesis of pulmonary emphysema in mice. *Int J Chron Obstruct Pulmon Dis* [Internet]. 2016 Jul [cited 2021 Oct 18];Volume 11:1705–12. Available from: <https://www.dovepress.com/critical-role-of-tumor-necrosis-factor-receptor-1-in-the-pathogenesis--peer-reviewed-article-COPD>
28. Ilyas M, Agussalim A, Megawati M, Massi N, Djaharuddin I, Bakri S, et al. Relationship between Vitamin D Level and Serum TNF- α Concentration on the Severity of Chronic Obstructive Pulmonary Disease: Vitamin D Level and Serum TNF- α related to the Severity of Chronic Obstructive Pulmonary Disease. *Open Access Maced J Med Sci* [Internet]. 2019 Jul 29 [cited 2021 Oct 18];7(14):2298–304. Available from: <https://spiroski.migration.publicknowledgeproject.org/index.php/mjms/article/view/oamjms.2019.663>

29. Mathanraj S, Kumar V, S. Y, Reddy V. Correlation of serum TNF alpha level with severity of chronic obstructive pulmonary disease. *Int J Res Med Sci* [Internet]. 2017 Jul 26 [cited 2021 Oct 18];5(8):3309. Available from: <http://www.msjonline.org/index.php/ijrms/article/view/3519>
30. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. *Cold Spring Harb Perspect Biol* [Internet]. 2014 Oct 1 [cited 2021 Oct 18];6(10):a016295–a016295. Available from: <http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a016295>
31. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* [Internet]. 2012 May 15 [cited 2021 Oct 18];185(10):1065–72. Available from: <http://www.atsjournals.org/doi/abs/10.1164/rccm.201110-1792OC>
32. Wei J, Xiong X, Lin Y, Zheng B, Cheng D. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. *PeerJ* [Internet]. 2015 Aug 27 [cited 2021 Oct 18];3:e1199. Available from: <https://peerj.com/articles/1199>
33. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. *Nat Rev Immunol* [Internet]. 2010 Mar [cited 2021 Oct 18];10(3):170–81. Available from: <http://www.nature.com/articles/nri2711>
34. Garantziotis S, Brass DM, Savov J, Hollingsworth JW, McElvania-TeKippe E, Berman K, et al. Leukocyte-Derived IL-10 Reduces Subepithelial Fibrosis Associated with Chronically Inhaled Endotoxin. *Am J Respir Cell Mol Biol* [Internet]. 2006 Dec [cited 2021 Oct 18];35(6):662–7. Available from: <http://www.atsjournals.org/doi/abs/10.1165/rcmb.2006-0055OC>
35. Rosenwasser LJ. Biologic activities of IL-1 and its role in human disease. Essayan DM, Fox CC, Levi-Schaffer F, Alam R, editors. *J Allergy Clin Immunol* [Internet]. 1998 Sep [cited 2021 Oct 12];102(3):344–50. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0091674998701186>
36. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1 β secretion. *Cytokine Growth Factor Rev* [Internet]. 2011 Aug [cited 2021 Oct 12];22(4):189–95. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1359610111000475>

37. Fields JK, Günther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. *Front Immunol* [Internet]. 2019 Jun 20 [cited 2021 Oct 12];10:1412. Available from: <https://www.frontiersin.org/article/10.3389/fimmu.2019.01412/full>
38. Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The role of interleukin-1 in general pathology. *Inflamm Regen* [Internet]. 2019 Dec [cited 2021 Oct 12];39(1):12. Available from: <https://inflammregen.biomedcentral.com/articles/10.1186/s41232-019-0101-5>
39. Anthonisen NR, Harding GKM. Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease. *Ann Intern Med*. 1987;106(2):9.
40. Viniol C, Vogelmeier CF. Exacerbations of COPD. *Eur Respir Rev* [Internet]. 2018 Mar 31 [cited 2021 Oct 17];27(147):170103. Available from: <http://err.ersjournals.com/lookup/doi/10.1183/16000617.0103-2017>
41. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. *Thorax* [Internet]. 2011 May 1 [cited 2021 Oct 17];66(5):430–7. Available from: <https://thorax.bmjjournals.org/lookup/doi/10.1136/thx.2010.154484>
42. Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis* [Internet]. 2015 Jul [cited 2021 Oct 17];1465. Available from: <http://www.dovepress.com/clinical-characteristics-of-patients-with-chronic-obstructive-pulmonary-peer-reviewed-article-COPD>
43. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for Prevention of Exacerbations of COPD. *N Engl J Med* [Internet]. 2011 Aug 25 [cited 2021 Oct 17];365(8):689–98. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa1104623>
44. Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med* [Internet]. 2016 May [cited 2021 Oct 17];4(5):390–

8. Available from:
<https://linkinghub.elsevier.com/retrieve/pii/S2213260016001004>
45. Osei ET, Brandsma C-A, Timens W, Heijink IH, Hackett T-L. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. *Eur Respir J* [Internet]. 2020 Feb [cited 2021 Oct 13];55(2):1900563. Available from:
<http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00563-2019>
46. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol* [Internet]. 2008 Mar [cited 2021 Oct 12];8(3):183–92. Available from:
<http://www.nature.com/articles/nri2254>
47. Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, Vanden Berghe T, et al. Role of IL-1 and the Nlrp3/caspase-1/IL-1 axis in cigarette smoke-induced pulmonary inflammation and COPD. *Eur Respir J* [Internet]. 2011 Nov 1 [cited 2021 Oct 13];38(5):1019–28. Available from:
<http://erj.ersjournals.com/cgi/doi/10.1183/09031936.00158110>
48. Botelho FM, Bauer CMT, Finch D, Nikota JK, Zavitz CCJ, Kelly A, et al. IL-1 α /IL-1R1 Expression in Chronic Obstructive Pulmonary Disease and Mechanistic Relevance to Smoke-Induced Neutrophilia in Mice. Chu HW, editor. *PLoS ONE* [Internet]. 2011 Dec 6 [cited 2021 Oct 13];6(12):e28457. Available from:
<https://dx.plos.org/10.1371/journal.pone.0028457>
49. Colarusso C, Terlizzi M, Molino A, Pinto A, Sorrentino R. Role of the inflammasome in chronic obstructive pulmonary disease (COPD). *Oncotarget* [Internet]. 2017 Oct 10 [cited 2021 Oct 13];8(47):81813–24. Available from:
<https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.17850>
50. Churg A, Zhou S, Wang X, Wang R, Wright JL. The Role of Interleukin-1 β in Murine Cigarette Smoke-Induced Emphysema and Small Airway Remodeling. *Am J Respir Cell Mol Biol* [Internet]. 2009 Apr [cited 2021 Oct 13];40(4):482–90. Available from:
<http://www.atsjournals.org/doi/abs/10.1165/rcmb.2008-0038OC>
51. Bafadhel M, McKenna S, TerrY S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. *Am J Respir Crit Care Med*. 2011;184(6):662–71.

52. Fu J, McDonald VM, Gibson PG. Airway IL-1 β and systemic inflammation as predictors of future exacerbation risk in asthma and COPD. :51.
53. Department of Economic and Social Affairs Population Division. World population ageing 2013. New York: United Nation; 2013. 3 p.
54. Muzarti D. Correlation between Anxiety and Depression with Quality of Life among Chronic Obstructive Pulmonary Disease Patients. *J Respir Indo*. 2019;39(2):121–9.
55. Tsai T-Y, Livneh H, Lu M-C, Tsai P-Y, Chen P-C, Sung F-C. Increased risk and related factors of depression among patients with COPD: a population-based cohort study. *BMC Public Health* [Internet]. 2013 Dec [cited 2021 Oct 31];13(1):976. Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-13-976>
56. Kwon H, Kim E. Factors contributing to quality of life in COPD patients in South Korea. *Int J Chron Obstruct Pulmon Dis* [Internet]. 2016 Jan [cited 2021 Oct 31];103. Available from: <https://www.dovepress.com/factors-contributing-to-quality-of-life-in-copd-patients-in-south-kore-peer-reviewed-article-COPD>
57. Oemiat R. KAJIAN EPIDEMIOLOGIS PENYAKIT PARU OBSTRUKTIF KRONIK (PPOK). 23(2):7.
58. Raherison C, Girodet P-O. Epidemiology of COPD. *Eur Respir Rev* [Internet]. 2009 Dec 1 [cited 2021 Nov 1];18(114):213–21. Available from: <http://err.ersjournals.com/cgi/doi/10.1183/09059180.00003609>
59. Donaldson GC. COPD exacerbations : Epidemiology. *Thorax* [Internet]. 2006 Feb 1 [cited 2021 Nov 1];61(2):164–8. Available from: <https://thorax.bmjjournals.org/lookup/doi/10.1136/thx.2005.041806>
60. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, et al. Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. *Ann Am Thorac Soc* [Internet]. 2015 Jan [cited 2021 Nov 1];12(1):27–34. Available from: <http://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.201409-413OC>
61. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. *Thorax* [Internet]. 2012 Nov [cited 2021 Nov 1];67(11):957–63.

Available from: <https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2011-201518>

62. Mahajan B, Vijayan VK, Agarwal MK, Bansal SK. Serum interleukin-1 β as a marker for differentiation of asthma and chronic obstructive pulmonary disease. *Biomarkers* [Internet]. 2008 Jan [cited 2021 Nov 2];13(7–8):713–27. Available from: <http://www.tandfonline.com/doi/full/10.1080/13547500802655367>
63. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1beta. *Monaldi Arch Chest Dis* [Internet]. 2016 Jan 19 [cited 2021 Nov 2];73(2). Available from: <http://monaldi-archives.org/index.php/macd/article/view/303>
64. Amer M, Wahba HodaMF, Ashmawi SamihaSA, Mabrouk R, Sharaf AhmadAE, Hamza S. Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease. *Lung India* [Internet]. 2010 [cited 2021 Nov 2];27(4):225. Available from: <http://www.lungindia.com/text.asp?2010/27/4/225/71956>
65. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, et al. Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD. *J Clin Immunol* [Internet]. 2009 Jul [cited 2021 Nov 2];29(4):508–16. Available from: <http://link.springer.com/10.1007/s10875-009-9286-8>
66. Oudijk E-JD. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. *Thorax* [Internet]. 2005 Jul 1 [cited 2021 Nov 2];60(7):538–44. Available from: <https://thorax.bmj.com/lookup/doi/10.1136/thx.2004.034009>